ABSTRACT
Objective To analyze and validate the key molecular targets correlated with the overall survival of patients with HER2-positive breast cancer.Methods First,the survival time and transcriptome data of patients with HER2-positive breast cancer in stage Ⅰ / Ⅱ and Ⅲ/Ⅳ were downloaded from the TCGA database.The significantly differential genes between overall survival ＜2 years and ＞8.5 years in stage Ⅰ / Ⅱ were picked out by edgeR package,and the pathways were enriched by KEGG.Similarly,the differential genes between overall survival ＜2 years and ＞7 years in stage Ⅲ/Ⅳ were analyzed.Furthermore,KEGG pathway analysis was performed using the differential genes overlapped by stage Ⅰ /Ⅱ and Ⅲ/Ⅳ.Second,the relationships between the expression levels of key node genes and other genes in enriched pathway and the overall survival of patients with HER2-positive breast cancer were validated by KMplot database.Last,the correlation between the activity of pathway enriched in KEGG and the resistance to anti-HER2 treatment was validated in HER2-positive breast cancer cell line BT474.Results In patients with stage Ⅰ / Ⅱ HER2-positive breast cancer whose overall survival was ＜2 years,PI3K/AKT was the 9th signaling pathway enriched by up-regulated differential genes.In patients with stage Ⅲ/Ⅳ whose overall survival was ＜2 years,PI3K/AKT was the 2nd signaling pathway enriched by up-regulated differential genes.Furthermore,PI3K/AKT was the first signal pathway enriched by the overlapping upregulated genes of patients in stage Ⅰ / Ⅱ and Ⅲ / Ⅳ whose overall survival was ＜2 years.Patients with high expression of PI3K and AKT (key node genes) or CFAP221 and COL4A6 (other genes) of PI3K/AKT pathway had shorter overall survival than those with low expression.PI3K inhibitors could enhance the growth inhibitory effect of HER2 small molecule inhibitor on HER2-positive breast cancer cell line BT474.Conclusions The overexpression of PI3K/AKT pathway is associated with the shorter overall survival in HER2-positive breast cancer patients,and associated with anti-HER2 resistance in HER2-positive breast cancer cell line.
ABSTRACT
<p><b>OBJECTIVE</b>To explore the effects of adenovirus delivered tissue inhibitor of metalloproteinases-3 (Ad-TIMP-3) on the biological behaviors of cervical cancer cell lines and to evaluate its potential application in cervical cancer gene therapy.</p><p><b>METHODS</b>We transferred Ad-TIMP-3 into cervical cancer cells. The TIMP-3 mRNA expression was assessed by RT-PCR, and the TIMP-3 and p53 protein expressions were assessed with Western blot. The apoptotic changes of cells were illustrated with morphology and DAPI staining. The viability of cells was determined with MTT assay. The abilities of in vitro invasion and adhesion were evaluated by the invasion and adhesion assays respectively.</p><p><b>RESULTS</b>After infection, the TIMP-3 mRNA and protein were significantly upregulated in a time-dependent manner. Overexpression of TIMP-3 markedly increased p53 protein level in spite of the backgrounds of p53 gene in cells. Ad-TIMP-3 infection induced massive apoptosis of cervical cancer cells with a marked bystander effect. The abilities of in vitro invasion and adhesion were inhibited significantly (P < 0.01). The cytotoxicity of Ad-TIMP-3 was significantly stronger than that of Ad-p53 (P < 0.05, P < 0.01).</p><p><b>CONCLUSIONS</b>Ad-TIMP-3 infection has cytotoxic effects on cervical cancer cells and can inhibit the expressions of these malignant phenotypes. Ad-TIMP-3 may be a potentially useful agent for cervical cancer gene therapy.</p>
Subject(s)
Female , Humans , Adenoviridae , Genetics , Apoptosis , Cell Adhesion , Cell Line, Tumor , Cell Survival , Gene Transfer Techniques , Neoplasm Invasiveness , Tissue Inhibitor of Metalloproteinase-3 , Genetics , Tumor Suppressor Protein p53 , Uterine Cervical NeoplasmsABSTRACT
<p><b>OBJECTIVE</b>To investigate the effects of adenovirus-delivered tissue inhibitor of metalloproteinases-3 ( Ad-TIMP-3) on sensitivity of cervical cancer cells to cisplatin and evaluate the potential application of this combined scheme in cervical cancer treatment.</p><p><b>METHODS</b>Cells of cervical cancer CaSKi cell line were infected with Ad-TIMP-3 in vitro. Apoptotic effect, cell cycle changes and p53 protein expression were detected. After combined treatment of those cells with cisplatin, colony formation test was performed and cytotoxicity was detected by MTT. The growth curve and tumor growth inhibition in vivo were evaluated.</p><p><b>RESULTS</b>The expressions of TIMP-3 mRNA and protein were significantly upregulated after transfection. As a result, massive apoptosis was induced and the cells were arrested at G2/M phase. Exogenous overexpression of TIMP-3 increased p53 protein level markedly in spite of the backgrounds of p53 gene in cells. Combined with cisplatin treatment, the cloning efficiency was decreased. A synergism was observed by isobolic method ( D < 1 ) in vitro and tumor growth was significantly inhibited in vivo.</p><p><b>CONCLUSION</b>Ad-TIMP-3 is a powerful proapoptotic agent. It increases sensitivity of the cells to cisplatin and the Ad-TIMP-3 gene therapy in combination with cisplatin could be a promising alternative in cervical cancer treatment.</p>
Subject(s)
Animals , Female , Humans , Mice , Adenoviridae , Genetics , Antineoplastic Agents , Pharmacology , Apoptosis , Genetics , Blotting, Western , Carcinoma, Squamous Cell , Genetics , Pathology , Therapeutics , Cell Cycle , Genetics , Cell Line, Tumor , Cisplatin , Pharmacology , Combined Modality Therapy , Genetic Therapy , Methods , HeLa Cells , Mice, Nude , RNA, Messenger , Genetics , Random Allocation , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-3 , Genetics , Metabolism , Transfection , Tumor Suppressor Protein p53 , Metabolism , Uterine Cervical Neoplasms , Genetics , Pathology , Therapeutics , Xenograft Model Antitumor Assays , MethodsABSTRACT
<p><b>OBJECTIVE</b>To explore the feasibility and mechanism of recombinant adenovirus Ad-pl4ARF in cancer gene therapy.</p><p><b>METHODS</b>The proliferation of different liver cancer cells was assessed by morphology and trypan blue assay. Cell apoptosis was confirmed by detecting phosphatidylserine (PS) externalization with Annexin V/PI double staining. The expression of related proteins was analyzed by Western bloting. Nude mouse model bearing subcutaneous transplanted BEL7402 tumor was established to study the therapeutic ability of Ad-pl4ARF.</p><p><b>RESULTS</b>Ad-pl4ARF suppressed cell growth and proliferation, and promoted cell apoptosis of cancer cell lines with different genetic background. Ad-pl4ARF inhibited growth of liver cancer cells ( HepG2, BEL7402) in a dose-dependent manner. Ad-pl4ARF lead to overexpression of Bax and p21, the downstream regulating genes of p53. In the experimental therapy on nude mice bearing subcutaneous transplanted BEL7402 tumor, Ad-pl4ARF suppressed tumor growth significantly.</p><p><b>CONCLUSION</b>pl4ARF is a short gene and with powerful function, which are consistent with the requirements for tumor suppressor genes used in gene therapy. It may play an important role in gene therapy against malignancies in the future.</p>